HMOX1 and coronary artery disorder: Given that HO-1 has significant anti-inflammatory therapeutic potential, recent research has pointed out HO-1-modified MSCs have an enhanced ability to attenuate inflammatory responses in ischemic heart disease [33], acute ischemic liver failure [34], lipopolysaccharide (LPS)-induced microvascular injury [35], and cisplatin-induced AKI [36].